AstraZeneca trials only after review by UK’s Drug and Safety Monitoring Board: Serum Institute

The decision to put the trials on hold was taken by the members of the DSMB after they were informed about the serious adverse events reported in Phase II/III trials in UK. “The subject has been diagnosed with neurological disorder,” it has informed the the Drug controller General Of India (DCGI).

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3bORTky
via IFTTT